210 related articles for article (PubMed ID: 18562053)
1. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.
Liu J; Yu Q; Stone GW; Yue FY; Ngai N; Jones RB; Kornbluth RS; Ostrowski MA
Vaccine; 2008 Jul; 26(32):4062-72. PubMed ID: 18562053
[TBL] [Abstract][Full Text] [Related]
2. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
3. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals.
Yu Q; Gu JX; Kovacs C; Freedman J; Thomas EK; Ostrowski MA
J Immunol; 2003 Feb; 170(4):1797-805. PubMed ID: 12574344
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.
Silva de Castro I; Gordon SN; Liu J; Bissa M; McKinnon K; Trinh HV; Doster MN; Schifanella L; Liyanage NP; Cao J; Cheng O; Foulds K; Roederer M; Koup RA; Shen X; Tomaras GD; Venzon DJ; Forthal DN; Fouts T; Montefiori DC; Tartaglia J; Rao M; Ostrowski M; Franchini G; Vaccari M
J Virol; 2020 Feb; 94(6):. PubMed ID: 31896599
[TBL] [Abstract][Full Text] [Related]
5. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals.
Engelmayer J; Larsson M; Lee A; Lee M; Cox WI; Steinman RM; Bhardwaj N
J Virol; 2001 Mar; 75(5):2142-53. PubMed ID: 11160718
[TBL] [Abstract][Full Text] [Related]
6. Development of TNFSF as molecular adjuvants for ALVAC HIV-1 vaccines.
Liu J; Ostrowski M
Hum Vaccin; 2010 Apr; 6(4):355-9. PubMed ID: 20372075
[TBL] [Abstract][Full Text] [Related]
7. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.
Stone GW; Barzee S; Snarsky V; Kee K; Spina CA; Yu XF; Kornbluth RS
J Virol; 2006 Feb; 80(4):1762-72. PubMed ID: 16439533
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
9. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.
Marovich MA; Mascola JR; Eller MA; Louder MK; Caudrelier PA; El-Habib R; Ratto-Kim S; Cox JH; Currier JR; Levine BL; June CH; Bernstein WB; Robb ML; Schuler-Thurner B; Steinman RM; Birx DL; Schlesinger-Frankel S
J Infect Dis; 2002 Nov; 186(9):1242-52. PubMed ID: 12402193
[TBL] [Abstract][Full Text] [Related]
10. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
[TBL] [Abstract][Full Text] [Related]
11. Characterization of antigen-specific immune responses induced by canarypox virus vaccines.
Bos R; van Duikeren S; van Hall T; Lauwen MM; Parrington M; Berinstein NL; McNeil B; Melief CJ; Verbeek JS; van der Burg SH; Offringa R
J Immunol; 2007 Nov; 179(9):6115-22. PubMed ID: 17947686
[TBL] [Abstract][Full Text] [Related]
12. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.
Ferrari G; Berend C; Ottinger J; Dodge R; Bartlett J; Toso J; Moody D; Tartaglia J; Cox WI; Paoletti E; Weinhold KJ
Blood; 1997 Sep; 90(6):2406-16. PubMed ID: 9310492
[TBL] [Abstract][Full Text] [Related]
13. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
[TBL] [Abstract][Full Text] [Related]
14. CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals.
Auten MW; Huang W; Dai G; Ramsay AJ
Vaccine; 2012 Apr; 30(17):2768-77. PubMed ID: 22349523
[TBL] [Abstract][Full Text] [Related]
15. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
16. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.
Egan MA; Pavlat WA; Tartaglia J; Paoletti E; Weinhold KJ; Clements ML; Siliciano RF
J Infect Dis; 1995 Jun; 171(6):1623-7. PubMed ID: 7769304
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of published studies.
Edupuganti S; Weber D; Poole C
HIV Clin Trials; 2004; 5(5):259-68. PubMed ID: 15562366
[TBL] [Abstract][Full Text] [Related]
19. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.
Zhang R; Zhang S; Li M; Chen C; Yao Q
Vaccine; 2010 Jul; 28(31):5114-27. PubMed ID: 20471443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]